Improving outcomes for chronic kidney disease (CKD) requires early identification and recognition by physicians. There are few data on rates of testing or use of diagnostic codes for CKD. A cross-sectional analysis was performed of patients who were older than 40 yr and had one or more laboratory tests between April 1, 2002, and March 31, 2003, at a Laboratory Corporation of America regional laboratory. Objectives were to determine the frequency of testing for serum creatinine; prevalence of CKD, defined as estimated GFR <60 ml/min per 1.73m 2 ; and sensitivity of diagnostic codes for CKD for patients with and without risk factors for CKD and with or without cardiovascular disease (CVD). Of the 277,111 patients, 19% had serum creatinine measured, compared with 33 and 71% who had measurements of serum glucose and lipids, respectively. Patients with hypertension, diabetes, and age >60 yr were more likely to be tested for serum creatinine with odds ratio (OR; 95% confidence interval) of 2.09 (2.05 to 2.14), 1.22 (1.19 to 1.25), and 1.24 (1.22 to 1.27) respectively. Among patients tested, 30% had CKD. Sensitivity and specificity of kidney disease diagnostic codes compared with CKD defined by estimated GFR <60 ml/min per 1.73 m 2 were 11 and 96%, respectively. In patients with hypertension, diabetes, age >60 years, and CVD, rates of testing and sensitivity of diagnostic codes were 53 and 14%, respectively. Low rates of testing for serum creatinine and insensitivity of diagnostic codes for CKD, even in high-risk patients, suggests inadequate physician awareness of CKD and limited utility of administrative databases for identification of patients with CKD.
A dverse outcomes associated with chronic kidney disease (CKD) are due, in part, to late detection of CKD, resulting in delays in diagnosis, treatment, and referral to a nephrologist (1) (2) (3) (4) . Clinical practice guidelines provide evidence-based recommendations for evaluation and management of CKD (5-8). Physician awareness of CKD is central to the success of these guidelines in achieving improved outcomes. Health care organizations and insurance plans can assist physicians in providing the recommended care by targeting appropriate patients for quality improvement activities. Some organizations maintain laboratory databases that can be used to identify patients with CKD (9) . However, in others, including Medicare, laboratory data are not available and diagnostic codes from claims data are used to identify CKD (10) . The frequency of patients with CKD who are identified through laboratory testing for serum creatinine and use of diagnostic codes for kidney disease has not been well described. Low rates of testing and use of diagnostic codes may indicate lack of awareness of CKD by physicians and limit utility of administrative databases for identification of patients with CKD.
We examined the frequency of testing for serum creatinine and the accuracy of diagnostic codes for CKD in one region of a national clinical commercial laboratory. We hypothesized that frequency of testing would be higher in high-risk groups but low compared with testing for other chronic conditions that are also risk factors for cardiovascular disease, such as diabetes and hyperlipidemia. We also hypothesized that diagnostic codes would identify only a small subset of the patients with CKD, defined as estimated GFR Ͻ60 ml/min per 1.73 m 2 , and that diagnostic codes are used preferentially in patients with more severe reduction in GFR.
Materials and Methods

Study Population
The study population included all people who were 40 yr of age or older and had at least one laboratory test performed between April 1, 2002 , and March 31, 2003 , at the Laboratory Corporation of America (LabCorp) regional laboratory located in Columbus, OH. This laboratory serves a population of 35 million in the Ohio, West Virginia, Illinois, northern Indiana, and western Pennsylvania regions. LabCorp provides approximately 20% of the medical laboratory testing to this region. Individuals who were pregnant during the year or who were on dialysis were excluded on the basis of the presence of a pregnancy-or dialysis-related diagnosis code. Individuals with missing identification numbers were also excluded.
Data Source
The database consisted of information that was submitted on the laboratory requisition and provided on the laboratory reports to the clinical providers. Physicians (providers) must supply diagnostic codes to order laboratory tests. Codes defined by the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) were used for this purpose.
Demographic and Clinical Characteristics
Hypertension, diabetes, and age Ͼ60 yr were defined as risk factors for CKD. CKD is highly associated with cardiovascular disease (CVD) (9, (11) (12) (13) . Patients with risk factors for CKD and with CVD were considered to be at highest risk for CKD. Diabetes, hypertension, and CVD were defined from an ICD-9-CM code for the condition submitted at least once during the measurement year on any laboratory test requisition. Given that the data set is limited to a 12-mo interval, we did not require two diagnostic codes for the definition of diabetes, as is generally required with the use of the larger claims-based administrative data sets (14) . We compared laboratory and ICD-9-CM-based definition for diabetes using standard cutoffs recommended by the American Diabetes Association (15) . Sensitivity and specificity of ICD-9-CM-based definitions were 81 and 85%, respectively, compared with the laboratory definition. To test the impact of the ICD-9-CM-based and lab-based definitions on identification of diabetes, we performed all analyses using both definitions. No substantive differences were seen, and all results reported here use the ICD-9-CM-based diagnosis. CVD codes were categorized into those related to cardiac disease (e.g., coronary artery disease, myocardial disease), cerebral vascular disease, and peripheral vascular disease. Diagnostic codes for all diseases are listed in the Appendix.
Outcomes of Interest
We considered three outcomes. First, we calculated the proportion of patients who were tested for kidney disease with serum creatinine on at least one occasion in a 12-mo period. We compared the number of patients who were tested for serum creatinine with the number of patients who received all laboratory tests necessary to evaluate other chronic diseases (e.g., diabetes, hyperlipidemia) and commonly ordered tests, such as complete blood count and electrolytes.
Second, we determined the prevalence of CKD, defined as estimated GFR Ͻ60 ml/min per 1.73 m 2 , among patients in whom serum creatinine was measured. The upper limit of normal for serum creatinine at LabCorp is 1.5 mg/dl for both men and women. Calibration of creatinine is necessary for accurate GFR estimates (16 -19 An inadequate number of patients with estimated GFR Ͻ15 ml/min per 1.73 m 2 were available to examine this group separately. A single estimated GFR of Ͻ60 ml/min per 1.73 m 2 was considered to be CKD as in other epidemiologic studies (9, 12, 20, 21) . In patients who had more than one measurement of serum creatinine, we examined the persistence of decreased levels of estimated GFR across time. Data on race were not available and could not be used in the estimation of GFR. Thus, the primary analysis assumed that all patients were not black. This has the effect of underestimating GFR by 21% for black individuals. Census data from the counties serviced by this laboratory report that 9% of the population is black (22). To test the impact of this assumption, we performed sensitivity analyses assuming a prevalence of black individuals in the study population of 9 and 18%.
Third, we assessed accuracy of ICD-9-CM codes related to kidney disease. ICD-9-CM codes were categorized into acute kidney disease, chronic kidney disease, dialysis, and kidney transplantation (see Appendix). Sensitivity, specificity, and predictive value were computed for the study sample and subgroups defined by risk factors for CKD and CVD. 
Statistical Analyses
Descriptive statistics are presented as frequencies or means with SD or medians with 5th and 95th percentiles, depending on the underlying distribution. Comparisons were conducted using 2 test or OR, as appropriate. The study was approved by the Institutional Review Board at Tufts-New England Medical Center.
Results
A total of 277,111 individuals had 4,015,562 tests in 489,389 visits that were performed from April 1, 2002, to March 31, 2003 , and processed at the Columbus, OH, laboratory of LabCorp. Table 1 shows the demographics and clinical char- Figure 1 . Frequency of testing for creatinine compared with other common laboratory tests by risk factor condition. Percentages are the patients who did or did not have the risk factor and were tested for each test. acteristics of the population. Of the patients who were older than 60 yr, 50% had either diabetes or hypertension.
Testing for Serum Creatinine
In the study population, 19% of patients had at least one measurement of serum creatinine ( 2 and 3, Figure 1 ). The median number of visits to the laboratory in individuals who did not have measurement of serum creatinine was one visit (59 maximum). For individuals who had all three risk factors and did not have a measurement of serum creatinine, the median number of visits was three visits (46 maximum). Patients with kidney disease codes were more likely to be tested for serum creatinine than patients without these codes (37%; OR 5.71 [5.48 to 5.95]).
Prevalence of CKD
In the patients who had measurement of serum creatinine, 30% had CKD (estimated GFR Ͻ60 ml/min per 1.73 m 2 ), and of those with CKD, 11% had estimated GFR Ͻ30 ml/min per 1.73 m 2 . Table 4 shows the mean estimated GFR and proportions who had estimated GFR Ն60, 30 to 59, and Ͻ30 ml/min per 1.73 m 2 in subgroups defined by risk factors for CKD, CVD, or presence of kidney disease codes. Significantly more patients with CKD risk factor conditions, CVD, and kidney disease codes had CKD. Sensitivity analysis assuming 9 and 18% prevalence of black individuals increased the mean GFR by only 2 and 3 ml/min per 1.73 m 2 , respectively, and decreased the prevalence of CKD by only 2.7 and 4.5%, respectively.
In 89% of women and 70% of men with CKD, serum creatinine results were within normal limits for the laboratory (Յ1.5 mg/dl; Figure 2 ). In patients with CKD but normal serum creatinine, median (range) estimated GFR was 52 (30 to 59) ml/min per 1.73 m 2 . Of the patients who had discordance between estimated GFR and serum creatinine, 76 and 69% of women and men, respectively, were older than 60 yr.
Accuracy of Diagnostic Codes for CKD
ICD-9-CM codes for kidney disease were used in 3% of all patients. Sensitivity of the codes for detecting patients with estimated GFR of Ͻ60 and Ͻ30 ml/min per 1.73 m 2 was 11 and 39%, respectively. Specificity of the codes was 98 and 96%, respectively. High specificity for CKD stages 3 to 5 suggests that physicians are not using CKD codes for earlier stages of CKD, detected by markers of kidney damages, such as albuminuria. Positive and negative predictive values of diagnostic codes for kidney disease for GFR Ͻ60 ml/min per 1.73 m 2 were 65 and 72%, respectively, and for GFR Ͻ30 ml/min per 1.73 m 2 were 24 and 98%, respectively. The positive predictive value of diagnostic codes for GFR Ͻ30 ml/min per 1.73 m 2 was lower than for GFR Ͻ60 ml/min per 1.73 m 2 because diagnostic codes for kidney disease are not stage specific and may be used appropriately in patients with GFR 30 to 59 ml/min per 1.73 m 2 . Sensitivity and specificity did not differ substantially by presence or absence of risk factors or CVD (data not shown). Table 5 shows the three outcomes described above according to groups defined by the presence or absence of risk factors for CKD and CVD. Even in high-risk groups, most patients are not tested, and among those tested, most are not identified by diagnostic codes. For patients who were in the highest risk group and did not have a serum creatinine, the median (maximum) number of visits to the laboratory was three (57). As expected, because sensitivity and specificity do not vary substantially across subgroups, the positive predictive value increases as the prevalence of disease increases. For patients who were older than 60 yr, the sensitivity of diagnostic codes for GFR estimates Ͻ60 and Ͻ30 ml/min per 1.73 m 2 was 10 and 37%, respectively, compared with 12 and 47%, respectively, in patients who were younger than 60 yr (P ϭ 0.004 and 0.001).
Outcomes in Subgroups Defined by Combinations of Risk Factors and CVD
Outcomes in the Subgroup of Patients with Repeated Measurements of Serum Creatinine
Among 53,601 patients with measurements of serum creatinine, 11,494 (21%) had more than one measurement. Of those, 13% had discordant results with regard to GFR estimates Ն or Ͻ60 ml/min per 1.73 m 2 . In the 2766 patients who had persistent reduction in GFR for 3 mo or longer, the sensitivity of diagnostic codes was 22%.
Discussion
Our results suggest that many patients with risk factors for CKD are not being tested for CKD, and most patients with CKD are not identified by diagnostic codes, even in patients who are at highest risk for CKD and even those with persistent reduction in GFR. These findings are particularly notable in comparison with the higher frequency of testing for serum glucose or lipids and the higher sensitivity of ICD-9-CM codes for diabetes. Altogether, these results suggest that physicians are not aware of CKD or its relationship to CVD, especially in comparison with awareness of other CVD risk factors, such as diabetes and hyperlipidemia. This highlights three important implications for improving outcomes for CKD.
First, current recommendations are regular testing for CKD in people who are at increased risk for CKD or have CVD (7,23,24); thus, these low rates of testing suggest lack of adherence to current recommendations. Although treatments of proven effectiveness are available, substantial improvement in patient outcomes requires early identification, appropriate evaluation, and management (25) . Therefore, the lack of adherence to the guidelines represents missed opportunities to initiate appropriate treatment strategies. In addition, the low levels of testing for anemia even in patients with known CKD (i.e., those with diagnostic codes for kidney diseases) suggests that care for patients with known CKD are not at recommended levels.
Second, the low frequency of testing and sensitivity of diagnostic codes for CKD should influence the interpretation of studies of CKD performed in clinical populations. It is likely that such studies included only a small fraction of patients with CKD, and studies that used diagnostic codes alone were more likely to include patients with a severe reduction in GFR (10, 21, 26, 27) . This raises important questions about the accuracy and generalizability of these studies. Studies of CKD in clinical populations should identify patients with CKD from laboratory tests, report the fraction of patients who were tested for CKD, and express results of outcomes and costs of care according to level of GFR, corresponding to CKD stage.
Third, improvement in quality of care is often the result of quality improvement programs implemented by large health care organizations. The low frequency of testing and use of diagnostic codes observed in this study suggests that use of administrative data to identify patients for inclusion in quality improvement programs for CKD may limit the effectiveness of these programs to only a small fraction of the patients with CKD, and when diagnostic codes alone are used, these patients are more likely to be in the later stages of CKD.
One potential reason for the low rates of awareness of CKD may be the relatively recent publication of guidelines that define CKD irrespective of cause (2002) Another reason for lack of awareness of CKD may be the discordance between serum creatinine and estimated GFR as has been shown in multiple previous populations and settings (28 -31). The discordance suggests that increased fre- (N ϭ 277,111) . Categories are not exclusive. quency of testing for serum creatinine without reporting estimated GFR is not likely to improve detection of CKD and is the basis for recommendations by national and international organizations for automatic GFR reporting whenever serum creatinine is ordered (5,7,23,32) and for implementation of these recommendations by large health organizations and clinical laboratories (18, 33) . Indeed, the one study to assess the impact of automatic reporting of GFR estimates showed that physicians' awareness of CKD improved from 22 to 88% with introduction of GFR reports by the clinical laboratory. In this study, we suspect that improvement in physicians' awareness was due to the concurrent educational sessions by a dedicated nephrologist over the study duration and to implementation in an academic medical center, where physicians may be more motivated to change their practice. It will be important to reassess frequency of serum creatinine measurements and accuracy of diagnostic codes after implementation of automatic GFR reporting in a general outpatient setting.
Lack of awareness is only one potential explanation for why physicians may not use diagnostic codes for kidney disease. A diagnosis of kidney disease is not required for justification of laboratory tests; therefore, physicians may preferentially code other diseases, such as hypertension or diabetes. In addition, physicians may not know how to use ICD-9-CM codes for CKD, given that the current ICD-9-CM classification system for CKD is based on cause and therefore is not consistent with the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative definition for CKD, which can be applied irrespective of cause. These issues are not particular to use of diagnostic codes used in association with laboratory tests and would also be expected to influence the accuracy of diagnostic codes in the claimsbased administrative databases. Irrespective of the reason, the lack of use of diagnostic codes limits use of administrative data for epidemiologic studies or quality improvement without explicit validation. This is the first study to document the low frequency of laboratory testing for serum creatinine and the low sensitivity of ICD-9-CM codes for kidney disease for CKD in a large national outpatient clinical laboratory. The strengths of this study are its wide age range, large fraction of patients with risk factors for CKD and CVD, and comparison of testing for serum creatinine with that of other common laboratory analytes. Importantly, the calibration of serum creatinine to the MDRD Study laboratory substantially improves the accuracy of the GFR estimates (16 -19) .
There are several limitations of this study. First, use of kidney disease codes was ascertained only from codes that were submitted to the laboratory. To minimize the impact of this issue, we used ICD-9-CM codes in association with any laboratory test (not just with serum creatinine tests) to increase the capture of relevant diagnostic codes. Possibly, the accuracy of diagnostic codes from other sources would have been higher, but this has not been reported to our knowledge. Note that similar to CKD, a diagnosis of hypertension is not required for justification of any laboratory test, yet 31% of the study population had a diagnosis of hypertension on the basis of diagnostic codes. Second, information on the demographics and clinical characteristics of the cohort was obtained from information that was submitted on laboratory requisitions, potentially leading to misclassification of patients with regard to risk factors for CKD or CVD. However, the use of a laboratory-based definition for diabetes did not substantially change the proportion with diabetes or the effect size in these subgroups. Third, race is not available in the data set. Census data show that approximately 9% of residents in this area are black (22), and it is known that black individuals are at higher risk for CKD (5,34). The sensitivity analysis showed the minimal impact on the mean GFR and prevalence of CKD if up to 18% of patients were black, but these analyses do not incorporate differential prevalence of CKD. Fourth, some patients may have had serum creatinine measurements at other laboratories during the study period rather than at LabCorp. The high rate of testing for lipids suggests that this is not a likely explanation. Furthermore, the number of visits to the laboratory in highrisk patients who did not have a serum creatinine measurement emphasizes the magnitude of missed opportunities for testing. Overall, we believe that these weaknesses do not seriously detract from the conclusions of our study.
Our findings suggest that physicians are not aware of CKD or its risk factors or associations with CVD. This would seriously limit physicians' ability to deliver quality care to patients with CKD. It also would limit the utility of laboratory and administrative databases for identification of patients with CKD for implementation of quality improvement programs. Integrated programs for other important chronic conditions, such as the Health Plan Employer Data and Information Set measures of the National Committee Quality Assurance (NCQA) and Quality Improvement Collaborations, are incentives for health care organizations to improve detection, evaluation, and management for these conditions. In contrast, no similar programs exist for CKD. This is due in part to its newly recognized status as a significant contributor to adverse outcomes and health care costs. This work provides emphasis for the importance of implementation programs recommended by the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative, National Kidney Disease Education Program, and other organizations. 
Diagnostic codes used in this analysis
